Liquid chromatography-tandem mass spectrometry method for simultaneous quantification of four triazole antifungal agents in human plasma

被引:34
作者
Verdier, Marie-Clemence [1 ]
Bentue-Ferrer, Daniele [1 ]
Tribut, Olivier [1 ]
Bellissant, Eric [1 ]
机构
[1] Univ Rennes 1, Univ Hosp, INSERM, Clin Investigat Ctr 0203, Rennes, France
关键词
antifungal agents; liquid chromatography-mass spectrometry (LC-MS/MS); therapeutic drug monitoring (TDM); DRUG-DRUG INTERACTIONS; POSACONAZOLE; VORICONAZOLE; FLUCONAZOLE; PHARMACOKINETICS; VALIDATION; ITRACONAZOLE; CYCLOSPORINE; HYDROXYITRACONAZOLE; RIFABUTIN;
D O I
10.1515/CCLM.2010.252
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Invasive fungal infections are an increasing cause of morbidity and mortality. Triazole antifungal agents are recommended for the prevention and treatment of such infections. Their broad inter-and intra-individual pharmacokinetic variability and the high probability of drug-drug interactions justify therapeutic drug monitoring (TDM). We developed a liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of four triazole antifungal agents (fluconazole, itraconazole, posaconazole, voriconazole) and one of their metabolites (hydroxy-itraconazole) in human plasma. Methods: After protein precipitation with acetonitrile (ACN), a C18 column was used for separation with a mobile phase consisting of 0.1% formic acid, water and ACN in a linear gradient from 20% to 70%, over 10 min. Detection was performed by electrospray ionization and quantification was performed using selected reaction monitoring transitions. Results: Total run time was 15 min. The method was validated for a range of 0.1-12 mu g/mL. Coefficients of variation were <9.5% and <13.8%, and accuracies were between <5.4% and +7.7% and between -10.8% and +10.4%, for intra-and inter-day validations, respectively. Conclusions: This method appears to be well suited to routine hospital practice for the TDM of triazole antifungal agents considering its time of analysis, range of concentrations measured, precision and accuracy. Clin Chem Lab Med 2010;48:1515-22.
引用
收藏
页码:1515 / 1522
页数:8
相关论文
共 33 条
[11]   Effects of fluconazole and clarithromycin on rifabutin and 25-O-desacetylrifabutin pharmacokinetics [J].
Jordan, MK ;
Polis, MA ;
Kelly, G ;
Narang, PK ;
Masur, H ;
Piscitelli, SC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (08) :2170-2172
[12]   Validation of an assay for voriconazole in serum samples using liquid chromatography-tandem mass spectrometry [J].
Keevil, BG ;
Newman, S ;
Lockhart, S ;
Howard, SJ ;
Moore, CB ;
Denning, DW .
THERAPEUTIC DRUG MONITORING, 2004, 26 (06) :650-657
[13]   An optimized analytical method of fluconazole in human plasma by high-performace liquid chromatgraphy with ultraviolet detection and its application to a bioequivalence study [J].
Kim, Sung-Su ;
Im, Ho-Taek ;
Kang, Il-Mo ;
Lee, Hyun-Su ;
Lee, Heon-Woo ;
Cho, Sung-Hee ;
Kim, Jong-Bin ;
Lee, Kyung-Tae .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2007, 852 (1-2) :174-179
[14]   Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men [J].
Krishna, G. ;
Parsons, A. ;
Kantesaria, B. ;
Mant, T. .
CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (03) :545-552
[15]   Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS [J].
Matuszewski, BK ;
Constanzer, ML ;
Chavez-Eng, CM .
ANALYTICAL CHEMISTRY, 2003, 75 (13) :3019-3030
[16]   HPLC analysis of the antifungal agent posaconazole in patients with haematological diseases [J].
Mueller, Carsten ;
Arndt, Margit ;
Queckenberg, Christian ;
Cornely, Oliver A. ;
Theisohn, Martin .
MYCOSES, 2006, 49 :17-22
[17]   The Enzymatic Basis of Drug-Drug Interactions with Systemic Triazole Antifungals [J].
Nivoix, Yasmine ;
Leveque, Dominique ;
Herbrecht, Raoul ;
Koffel, Jean-Claude ;
Beretz, Laurence ;
Ubeaud-Sequier, Genevieve .
CLINICAL PHARMACOKINETICS, 2008, 47 (12) :779-792
[18]   Drug-Drug Interactions of Triazole Antifungal Agents in Multimorbid Patients and Implications for Patient Care [J].
Nivoix, Yasmine ;
Ubeaud-Sequier, Genevieve ;
Engel, Pauline ;
Leveque, Dominique ;
Herbrecht, Raoul .
CURRENT DRUG METABOLISM, 2009, 10 (04) :395-409
[19]   Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients [J].
Osowski, CL ;
Dix, SP ;
Lin, LS ;
Mullins, RE ;
Geller, RB ;
Wingard, JR .
TRANSPLANTATION, 1996, 61 (08) :1268-1272
[20]   Voriconazole plasma monitoring [J].
Pasqualotto, A. C. ;
Shah, M. ;
Wynn, R. ;
Denning, D. W. .
ARCHIVES OF DISEASE IN CHILDHOOD, 2008, 93 (07) :578-581